Praxis Precision Medicines Announces Plans to Begin Ulixacaltamide Phase 3 in…
Phase 3 program to include one parallel group study and one randomized withdrawal study mADL11 as primary endpoint Single 60 mg/day dose to be tested BOSTON, June 09,…